AMB-CHMINACA

AMB-CHMINACA is a synthetic cannabinoid that has been identified in herbal blends. Its name refers to its structure: it is an indazole-based synthetic cannabinoid. It is the indazole analogue of AB-CHMINACA, which features a cyclohexyl group replaced by an isopropyl group.

History

AMB-CHMINACA was first identified in Japan in 2014. It was originally developed by Pfizer in 2009 as an analgesic medication, but was not pursued for human use. Since 2014, it has been identified in smoking blends.

Pharmacology

Like other synthetic cannabinoids, AMB-CHMINACA acts as a potent agonist for the CB1 receptor, with a Ki of 0.45 nM. It is 16x more potent than JWH-018, a common synthetic cannabinoid found in various herbal blends.

Legal Status

As of October 2015, AMB-CHMINACA is a Schedule I controlled substance in the United States.

See Also

• Synthetic cannabinoids
• AB-CHMINACA
• JWH-018

References

AMB-CHMINACA Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski